SciSparc Ltd. Announces Key Developments in Merger and Patent Application

SEC Filing 6-K (0001213900-25-069979)

SciSparc Ltd. (Nasdaq: SPRC) reported significant updates in its July 2025 Form 6-K filing. The company announced the filing of an international patent application for a novel combination therapy targeting weight loss and fatty liver disease, developed in collaboration with Clearmind Medicine Inc. This therapy combines 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) with Palmitoylethanolamide (PEA), aiming to address obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Additionally, SciSparc provided updates on its proposed merger with AutoMax Motors Ltd., noting that the SEC has declared the Form F-4 registration statement effective. Shareholder meetings to approve the merger are scheduled for August 2025. The company also extended the deadline for definitive agreements with Miza III Ventures Inc. to October 15, 2025.